Related Experiment Video
Updated: Feb 10, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025
Breakthrough Fungal Infections in Patients With Leukemia Receiving Isavuconazole
Caitlin R Rausch1, Adam J DiPippo1, Prithviraj Bose2
1Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston.
Abstract:
We retrospectively assessed breakthrough invasive fungal infections (b-IFIs) in 100 consecutive patients with leukemia receiving single-agent isavuconazole; 13 had documented b-IFIs (candidiasis in 6, mucormycosis in 4). All b-IFIs were observed in patients with prolonged neutropenia and active leukemia.
Insights
Breakthrough invasive fungal infections occurred in 13% of leukemia patients on isavuconazole. These infections were linked to prolonged neutropenia and active leukemia, highlighting key risk factors.
Area of Science:
- Mycology
- Hematology
- Infectious Diseases
Background:
- Invasive fungal infections (IFIs) are a significant cause of morbidity and mortality in immunocompromised patients, particularly those with hematologic malignancies.
- Leukemia patients are at high risk for IFIs due to prolonged neutropenia and disease-related immune dysfunction.
- Isavuconazole is a broad-spectrum triazole antifungal agent used for treating IFIs.
Purpose of the Study:
- To retrospectively assess the incidence and characteristics of breakthrough invasive fungal infections (b-IFIs) in leukemia patients treated with single-agent isavuconazole.
Main Methods:
- Retrospective analysis of 100 consecutive leukemia patients receiving single-agent isavuconazole.
- Documentation and classification of breakthrough invasive fungal infections, including candidiasis and mucormycosis.
Main Results:
- Thirteen out of 100 patients (13%) experienced documented b-IFIs.
- The most common b-IFIs were candidiasis (6 cases) and mucormycosis (4 cases).
- All b-IFIs occurred in patients with prolonged neutropenia and active leukemia.
Conclusions:
- Single-agent isavuconazole may be associated with breakthrough invasive fungal infections in leukemia patients.
- Prolonged neutropenia and active leukemia are critical risk factors for developing b-IFIs even with azole antifungal therapy.
- Further prospective studies are warranted to evaluate the efficacy and safety of isavuconazole in this high-risk population.
More Related Videos
06:48In Ovo Xenografting of Patient-Derived Acute Lymphoblastic Leukemia (ALL) Cells (PDX-ALL)
Published on: August 1, 2025
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
Related Concept Videos
Receiver Operating Characteristic Plot
Fungal Group Zygomycota
Fungal Phylum Microsporidia
Fungal Phylum Ascomycota
Fungal Phylum Basidiomycota
Infection
The chain begins with pathogens: bacteria, viruses, fungi, prions, or parasites such as protozoa helminths. These can be present on the skin as transient or resident flora, or they can be acquired from the environment. Identifying and treating the type of infection and...